Nouvel Hopital Civil Strasbourg
- Address
- lock Available on a paid plan
Neoplasms
The ICU at Nouvel Hopital Civil Strasbourg is conducting research on prostatic adenocarcinoma with a high risk of recurrence, evaluating the impact of postoperative hormonal therapy on long‑term outcomes.
- Adjuvant hormonal therapy after radical prostatectomy
- Long‑term survival without metastasis
- Risk reduction in high‑recurrence patients
Findings aim to improve survivorship and guide treatment decisions for men facing aggressive prostate cancer.
Respiratory Tract Diseases
In the intensive care setting, investigators are studying acute respiratory tract infection to determine how various interventions influence 90‑day all‑cause mortality and recovery trajectories.
- Multifactorial adaptive platform trials
- Evaluation of diverse therapeutic strategies
- Monitoring of daily illness progression and recovery
The goal is to identify optimal care pathways that reduce deaths and hasten patient recovery.
Virus Diseases
Researchers are assessing a simplified regimen for HIV–positive individuals, focusing on maintaining virological success with two‑drug combinations.
- Non‑inferiority comparison of two‑drug regimens
- Maintenance of viral suppression over 48 weeks
- Simplified treatment strategies for long‑term management
This work seeks to expand safe therapeutic options while preserving the health of people living with HIV.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 4 therapeutic areas and 15 of 52 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 52 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Nouvel Hopital Civil Strasbourg
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Assessment of Feasibility and Safety of a Polymeric Medical Device with Autologous Bone Marrow-Derived Mesenchymal Stem Cells for Knee Femoral Cartilage Lesions | Lamina Therapeutics | Phase I | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 52 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Levofloxacin | 2 | Unknown | 2016-02-19 | 2023-10-26 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.